C-met binding was examined at two HGF-doses (250 ng/ml and 500 ng/ml in PBS) by sandwich ELISA-like assay on recombinant c-met-Fc chimera as in Figure 1e, and significant changes in optical absorbance subtracted by a baseline level (negative control without HGF, bar 1 ) were depicted in Figure 2a (left column)
Trends in first-time prescribing First-time prescribing rates (first-time GLP-1 RA prescriptions per total prescriptions) increased from 1.4% in December 2025 to 1.6% in March 2026 (+13.3%)
GLPs and Heart Health: What the Research Is Showing Cardiovascular health is another area where GLPs are showing promise
2014: p
15 Cancers GLP-1s have been investigated for their impact in reducing the risk of obesity-related cancers (OACs) such as colorectal cancer, esophageal, breast, colorectal, endometrial, gallbladder, stomach, kidney, ovarian, pancreatic, and thyroid cancer, as well as hepatocellular carcinoma, meningioma, and multiple myeloma
These medications are administered subcutaneously and work through systemic receptor activation, independent of gallbladder function or bile storage